106 related articles for article (PubMed ID: 6883930)
1. Hemodialysis clearance of total and unbound lidocaine.
Jacobi J; McGory RW; McCoy H; Matzke GR
Clin Pharm; 1983; 2(1):54-7. PubMed ID: 6883930
[TBL] [Abstract][Full Text] [Related]
2. Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis.
De Martin S; Orlando R; Bertoli M; Pegoraro P; Palatini P
Clin Pharmacol Ther; 2006 Dec; 80(6):597-606. PubMed ID: 17178261
[TBL] [Abstract][Full Text] [Related]
3. Effect of hemodialysis on total body clearance of chloramphenicol.
Slaughter RL; Cerra FB; Koup JR
Am J Hosp Pharm; 1980 Aug; 37(8):1083-6. PubMed ID: 7405936
[TBL] [Abstract][Full Text] [Related]
4. Hemodialysis clearance of ethosuximide in patients with chronic renal disease.
Marbury TC; Lee CS; Perchalski RJ; Wilder BJ
Am J Hosp Pharm; 1981 Nov; 38(11):1757-60. PubMed ID: 7304633
[TBL] [Abstract][Full Text] [Related]
5. Hemodialysis clearance and total body elimination of carbamazepine during chronic hemodialysis.
Lee CS; Wang LH; Marbury TC; Bruni J; Perchalski RJ
Clin Toxicol; 1980 Oct; 17(3):429-38. PubMed ID: 7449356
[TBL] [Abstract][Full Text] [Related]
6. Effect of peritonitis on plasma and dialysate alpha 1-acid glycoprotein concentrations in peritoneal dialysis patients.
Bohenek WS; Johnson CA; Ateshkadi A; Oxton LL; Zimmerman SW
Clin Pharm; 1993 Aug; 12(8):602-5. PubMed ID: 8222525
[TBL] [Abstract][Full Text] [Related]
7. Hemodialysis of mefenamic acid in uremic patients.
Wang LH; Lee CS; Marbury TC
Am J Hosp Pharm; 1980 Jul; 37(7):956-8. PubMed ID: 7395889
[TBL] [Abstract][Full Text] [Related]
8. Comparison of temsirolimus pharmacokinetics in patients with renal cell carcinoma not receiving dialysis and those receiving hemodialysis: a case series.
Lunardi G; Armirotti A; Nicodemo M; Cavallini L; Damonte G; Vannozzi MO; Venturini M
Clin Ther; 2009 Aug; 31(8):1812-9. PubMed ID: 19808140
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of dyphylline elimination by uremic patients.
Lee CC; Wang LH; Majeske BL; Marbury TC
J Pharmacol Exp Ther; 1981 May; 217(2):340-4. PubMed ID: 7229976
[TBL] [Abstract][Full Text] [Related]
11. [Factors which influence phosphorus removal in hemodialysis].
Gallar P; Ortiz M; Ortega O; Rodríguez I; Seijas V; Carreño A; Oliet A; Vigil A
Nefrologia; 2007; 27(1):46-52. PubMed ID: 17402879
[TBL] [Abstract][Full Text] [Related]
12. Intracorporeal glucose disposal during hemodialysis after a standardized glucose load.
Schneditz D; Hafner-Giessauf H; Holzer H; Thomaseth K
ASAIO J; 2010; 56(3):204-9. PubMed ID: 20168210
[TBL] [Abstract][Full Text] [Related]
13. pO2 and pCO2 increment in post-dialyzer blood: the role of dialysate.
Sombolos KI; Bamichas GI; Christidou FN; Gionanlis LD; Karagianni AC; Anagnostopoulos TC; Natse TA
Artif Organs; 2005 Nov; 29(11):892-8. PubMed ID: 16266303
[TBL] [Abstract][Full Text] [Related]
14. Safety of 96-hour incision-site continuous infusion of ropivacaine for postoperative analgesia after bowel cancer resection.
Corso OH; Morris RG; Hewett PJ; Karatassas A
Ther Drug Monit; 2007 Feb; 29(1):57-63. PubMed ID: 17304151
[TBL] [Abstract][Full Text] [Related]
15. Chloramphenicol hemodialysis clearance.
Blouin RA; Erwin WG; Dutro MP; Bustrack JA; Rowse KL
Ther Drug Monit; 1980; 2(4):351-4. PubMed ID: 7222188
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
[TBL] [Abstract][Full Text] [Related]
17. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
18. Influence of enhanced alpha-1-acid glycoprotein concentration on protein binding, pharmacokinetics and antiarrhythmic effect of lidocaine in the dog.
De Rick AF; Belpaire FM; Dello C; Bogaert MG
J Pharmacol Exp Ther; 1987 Apr; 241(1):289-93. PubMed ID: 3572791
[TBL] [Abstract][Full Text] [Related]
19. Increased binding of beta-2-microglobulin to blood cells in dialysis patients treated with high-flux dialyzers compared with low-flux membranes contributed to reduced beta-2-microglobulin concentrations. Results of a cross-over study.
Traut M; Haufe CC; Eismann U; Deppisch RM; Stein G; Wolf G
Blood Purif; 2007; 25(5-6):432-40. PubMed ID: 17957097
[TBL] [Abstract][Full Text] [Related]
20. Dialysis treatment of acute chromium intoxication and comparative efficacy of peritoneal versus hemodialysis in chromium removal.
Schiffl H; Weidmann P; Weiss M; Massry SG
Miner Electrolyte Metab; 1982 Jan; 7(1):28-35. PubMed ID: 7169974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
